Secretory Phospholipase A2-IIA and Cardiovascular Disease A Mendelian Randomization Study
نویسندگان
چکیده
Guardiola, M; Cooper, JA; Palmen, J; Hubacek, JA; Carruthers, KF; Horne, BD; Brunisholz, KD; Mega, JL; van Iperen, EP; Li, M; Leusink, M; Trompet, S; Verschuren, JJ; Hovingh, GK; Dehghan, A; Nelson, CP; Kotti, S; Danchin, N; Scholz, M; Haase, CL; Rothenbacher, D; Swerdlow, DI; Kuchenbaecker, KB; Staines-Urias, E; Goel, A; Hooft, FV; Gertow, K; de Faire, U; Panayiotou, AG; Tremoli, E; Baldassarre, D; Veglia, F; Holdt, LM; Beutner, F; Gansevoort, RT; Navis, GJ; Leach, IM; Breitling, LP; Brenner, H; Dallmeier, D; Franco-Cereceda, A; Boer, J; Stephens, JW; Hofker, MH; Tedgui, A; Hofman, A; Uitterlinden, AG; Adamkova, V; Pitha, J; OnlandMoret, NC; Cramer, MJ; Nathoe, HM; Spiering, W; Klungel, OH; Kumari, M; Whincup, PH; Morrow, DA; Braund, PS; Hall, AS; Olsson, AG; Doevendans, PA; Trip, MD; Tobin, MD; Hamsten, A; Watkins, H; Koenig, W; Nicolaides, AN; Teupser, D; Day, IN; Carlquist, JF; Gaunt, TR; Ford, I; Sattar, N; Tsimikas, S; Schwartz, GG; Lawlor, DA; Morris, RW; Sandhu, MS; Poledne, R; Maitlandvan der Zee, AH; Khaw, KT; Keating, BJ; van der Harst, P; Price, JF; Mehta, SR; Yusuf, S; Witteman, JC; Franco, OH; Jukema, JW; de Knijff, P; Tybjaerg-Hansen, A; Rader, DJ; Farrall, M; Samani, J; Kivimaki, M; Fox, KA; Humphries, SE; Anderson, JL; Boekholdt, SM; Palmer, TM; Eriksson, P; Par, G; Hingorani, AD; Sabatine, MS; Mallat, Z; Casas, JP; Talmud, PJ (2013) Secretory Phospholipase A2IIA and Cardiovascular Disease: a Mendelian randomization study. Journal of the American College of Cardiology. ISSN 0735-1097 DOI: 10.1016/j.jacc.2013.06.044
منابع مشابه
Deciphering the Causal Role of sPLA2s and Lp-PLA2 in Coronary Heart Disease.
Over the last 10 to 15 years, animal and human observational studies have identified elevated levels of both proinflammatory secretory phospholipase A2-IIA and lipoprotein-associated phospholipase A2 as potential risk factors for coronary heart disease. However, Mendelian randomization, a genetic tool to test causality of a biomarker, and phase III randomized controlled trials of inhibitors of ...
متن کاملNovel genetic approach to investigate the role of plasma secretory phospholipase A2 (sPLA2)-V isoenzyme in coronary heart disease: modified Mendelian randomization analysis using PLA2G5 expression levels.
BACKGROUND Secretory phospholipase A2 (sPLA2) enzymes are considered to play a role in atherosclerosis. sPLA2 activity encompasses several sPLA2 isoenzymes, including sPLA2-V. Although observational studies show a strong association between elevated sPLA2 activity and CHD, no assay to measure sPLA2-V levels exists, and the only evidence linking the sPLA2-V isoform to atherosclerosis progression...
متن کاملType II Secretory Phospholipase A2 and Prognosis in Patients with Stable Coronary Heart Disease: Mendelian Randomization Study
BACKGROUND Serum type II secretory phospholipase A(2) (sPLA(2)-IIa) has been found to be predictive of adverse outcomes in patients with stable coronary heart disease. Compounds targeting sPLA(2)-IIa are already under development. This study investigated if an association of sPLA(2)-IIa with secondary cardiovascular disease (CVD) events may be of causal nature or mainly a matter of confounding ...
متن کاملExpression of type IIA secretory phospholipase A2 inhibits cholesteryl ester transfer protein activity in transgenic mice.
OBJECTIVE High circulating levels of group IIA secretory phospholipase A2 (sPLA2-IIA) activity and mass are independent cardiovascular risk factors. Therefore, inhibition of sPLA2-IIA may be a target for the treatment of atherosclerotic cardiovascular disease. The present study evaluated the effects of sPLA2-IIA inhibition with varespladib acid in a novel mouse model, human apolipoprotein B (ap...
متن کاملElevated Type II Secretory Phospholipase A2 Increases the Risk of Early Atherosclerosis in Patients with Newly Diagnosed Metabolic Syndrome
A critical association between type II secretory phospholipase A2 (sPLA2-IIa) and established atherosclerotic cardiovascular disease has been demonstrated. However, the contribution of sPLA2-IIa to early atherosclerosis remains unknown. This study investigated the association between early-stage atherosclerosis and sPLA2-IIa in metabolic syndrome (MetS) patients. One hundred and thirty-six MetS...
متن کامل